LOGC Stock Performance, Insider Transaction and News

LOGC - LogicBio Therapeutics, Inc.

Market Cap	68.23M	P/E	-	EPS this Y	41.90%	Ern Qtrly Grth	-
Income	-26.54M	Forward P/E	-3.39	EPS next Y	15.30%	50D Avg Chg	41.00%
Sales	10.76M	PEG	-	EPS past 5Y	-	200D Avg Chg	173.00%
Dividend	N/A	Price/Book	4.34	EPS next 5Y	-	52W High Chg	-39.00%
Recommedations	2.50	Quick Ratio	1.87	Shares Outstanding	32.96M	52W Low Chg	705.00%
Insider Own	8.93%	ROA	-30.31%	Shares Float	16.51M	Beta	-
Inst Own	48.71%	ROE	-97.40%	Shares Shorted/Prior	274.42K/51.61K	Price	2.07
Gross Margin	-185.15%	Profit Margin	-246.71%	Avg. Volume	529,309	Target Price	2.50
Oper. Margin	-240.64%	Earnings Date	Nov 14	Volume	152,923	Change	0.00%

Healthcare | Biotechnology | United States

About LogicBio Therapeutics, Inc.

LogicBio Therapeutics, Inc., a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms. The company's GeneRide technology is a new approach to precise gene insertion harnessing a cell's natural deoxyribonucleic acid; and gene delivery platform, sAAVy is an adeno-associated virus, which is designed to optimize gene delivery for treatments in a range of indications and tissues. Its lead product candidate is LB-001 that is in Phase I/II clinical trials for the treatment of methylmalonic acidemia. The company has a collaboration with Children's Medical Research Institute to develop next-generation capsids for gene therapy and gene editing applications in the liver, as well as additional tissues; and a collaboration agreement with Takeda Pharmaceutical Company Limited to develop LB-301, an investigational therapy for the treatment of Crigler-Najjar syndrome. The company also has a research collaboration, license, and option agreement with CANbridge Care Pharma Hong Kong Limited; and collaboration agreement with Daiichi Sankyo Company. The company was incorporated in 2014 and is headquartered in Lexington, Massachusetts. As of November 15, 2022, LogicBio Therapeutics, Inc. operates as a subsidiary of Alexion Pharmaceuticals, Inc..

LOGC Chatroom

fla Posted - 6 months ago

$LOGC [15s. delayed]: Issued Press Release on May 17, 11:24:00: Rare Diseases Market is projected to grow at a CAGR of 12.27% by 2033: Vis https://s.flashalert.me/IkoHvt

Quantisnow Posted - 6 months ago

$LOGC 📰 Rare Diseases Market is projected to grow at a CAGR of 12.27% by 2033: Visiongain https://quantisnow.com/i/4519668?utm_source=stocktwits 45 seconds delayed.

BiotechValues Posted - 6 months ago

$SRZN next payment this year from BI is nearly the size of the entire market cap. Boehringer would be crazy not to buy them under cash value of $2+. Could get all assets for free, keep the ones they want, and sell the rest off. This has $logc, who was bought for 600% premium, all over it.

GameOver4u83 Posted - 7 months ago

@skyrockets_Inc @BiotechValues @SDBiotechInvestor hey guys this could pull a $LOGC tomorrow $.39 to $2.00…could you imagine me doing that shit??? Mental masturbation is helluva drug

fla Posted - 03/31/23

$LOGC [15s. delayed]: Issued Press Release on March 31, 11:35:00: Rare Diseases Market is projected to grow at a CAGR of 12.27% by 2033: V https://s.flashalert.me/GW3FQ

Quantisnow Posted - 03/31/23

$LOGC 📰 Rare Diseases Market is projected to grow at a CAGR of 12.27% by 2033: Visiongain Reports Ltd https://quantisnow.com/i/4279091?utm_source=stocktwits This and other insights appear 45 seconds early at 💪 https://quantisnow.com/feed 💪

Frankie85 Posted - 03/31/23

@JuliusGenius Becouse you know nothing of the markets ! $LOGC Bought for 700% from Astrazeneca . Traded 30 Sept 2022 at 0.2725 to 2.01 on 3 Oct 2022 . Know that you are served you can go hiding yourself for the weekend .

BiotechValues Posted - 03/30/23

$SRZN will likely be the next $LOGC. LOGC was early stage and trading depressed at around the same market cap. It was bought out for 700% premium by AZ. No way partner BI or another pharma doesn't make a play on this at 80% below cash and $15M market cap. https://www.marketwatch.com/story/logicbios-stock-skyrockets-after-buyout-bid-for-a-667-premium-2022-10-03